Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 9501–9550 of 18437
On June 18, 2023, Christopher Chipman notified the Chairman of the Board of Directors of the Company of his decision to resign from his position as the Company’s Chief Financial Officer to pursue other opportunities.
Effective as of June 20, 2023, the Board of Directors of Virpax Pharmaceuticals, Inc. (the “Company”) appointed Vinay Shah to serve as the Company’s Chief Financial Officer.
On June 14, 2023, following the previously reported departure of the former Chief Financial Officer of Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), the Company’s board of directors appointed William Elder, Diffusion’s General Counsel and Corporate Secretary, as the Company’s principal financial officer.
replacing Brent Suen as President and filling the role of Chief Operating Officer which was previously vacant. Brent Suen will continue in his role as Chief Executive Officer.
Chris Suh to step down as Chief Financial Officer with a departure date of June 30, 2023
Stuart Canfield was appointed Executive Vice President, Chief Financial Officer, effective June 20, 2023
The agreement provides for Ms. Rentler to continue as CEO through and until January 31, 2026 (the end of fiscal year 2025), subject to any earlier selection of a successor as CEO, at which time Ms. Rentler will cease to be the Company’s Chief Executive Officer, and will become a Senior Advisor for the remainder of her employment term, through March 31, 2027.
Christopher Young, who has served as the Company’s Interim Chief Executive Officer since January 2, 2023, will step down from that role effective the same date, and will continue in his role as Chief Financial Officer and Treasurer.
appointed Michael Christenson as the Company’s Chief Executive Officer, effective as of July 1, 2023.
On June 13, 2023, Salona Global Medical Device Corporation (the "Company") exercised its right to terminate the employment of Luke Faulstick as the Company's President and Chief Executive Officer.
On June 13, 2023, upon terminating Mr. Faulstick, the Company appointed Michael Seckler, 58, to the position of Interim Chief Executive Officer, effective immediately.
On June 20, 2023, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing the appointment of Jennifer Cote as the Company’s Chief Financial Officer and Treasurer effective as of June 19, 2023.
John C. Redett, 55, Head of Global Financial Services, will become Chief Financial Officer and Head of Corporate Strategy, effective October 1, 2023.
On June 20, 2023, The Carlyle Group Inc. (the “Company” or “Carlyle”) announced that Curtis L. Buser, Chief Financial Officer, will retire from the Company, effective December 31, 2023.
Mr. Darrell will replace Benno Dorer, who has been serving as the Company’s Interim President and Chief Executive Officer
approved the appointment of Bracken Darrell as President and Chief Executive Officer of the Company, effective as of July 17, 2023
Effective immediately, on June 16, 2023, the Board of Directors (the “ Board ”) of Cano Health, Inc. (the “ Company ”) elected the Company’s current Chief Strategy Officer, Mr. deMarquette (“ Mark ”) Kent, as the Company’s Interim Chief Executive Officer (the “ Interim CEO ”).
Mr. Kent will replace Dr. Marlow Hernandez, who tendered his resignation as the Company’s Chief Executive Officer, as well as all positions he holds at the Company’s subsidiaries, effective immediately on June 16, 2023.
Brian Linscott departing the Company as of June 16, 2023
appointing Kirk Davis as Chief Executive Officer and nominating Mr. Davis to the Board, effective as of June 19, 2023
the Company appointed Timothy Mullany as its Chief Financial Officer, effective as of July 10, 2023
the Company has appointed Ryan Blust, the Company’s Vice President, Finance, to serve as its Interim Chief Financial Officer, effective immediately
Mr. D’Amico’s resignation as Chief Financial Officer was effective immediately.
As of July 5, 2023, Ricky Hopson will cease to serve as Interim Chief Financial Officer and principal financial officer of the Company and, after supporting Mr. Masanovich in his transition, will return to a business leadership role at the Company.
Catalent, Inc. (“ Catalent ” and, together with its subsidiaries, the “ Company ”), announced the appointment of Matti Masanovich as Senior Vice President and Chief Financial Officer, effective as of July 5, 2023.
On June 20, 2023, Visa Inc. (“Visa,” or the “Company”) announced that Chris Suh, 52, has been appointed to serve as Executive Vice President, Chief Financial Officer (“CFO”) of the Company, effective August 1, 2023.
Mr. Suh succeeds Vasant Prabhu, who is departing the Company on September 30, 2023.
On June 20, 2023, Hovnanian Enterprises, Inc. (the “Company”) announced that J. Larry Sorsby, Executive Vice President and Chief Financial Officer, intends to retire from the Company effective October 31, 2023.
In connection with Mr. Sorsby’s retirement, Brad G. O’Connor, age 52, has been appointed Chief Financial Officer, effective November 1, 2023.
On June 15, 2023, Rudolph A. Lutterschmidt tendered his resignation to the Company’s Board of Directors as Vice-President and Chief Financial Officer of Nocopi Technologies, Inc. (the “ Company ”), effective June 19, 2023.
On June 15, 2023, Debra Glickman, age 56, was appointed by the Company’s Board of Directors to serve as the Company’s Chief Financial Officer effective June 19, 2023.
Dusan Zindovic was appointed as the Company’s Interim Chief Executive Officer and Interim Chief Financial Officer on June 20, 2023.
On June 20, 2023, Danilo Vukadinovic resigned as the Company’s Interim Chief Executive Officer and Interim Chief Financial Officer.
On June 20, 2023, Danilo Vukadinovic resigned as the Company’s Interim Chief Executive Officer and Interim Chief Financial Officer.
Dusan Zindovic was appointed as the Company’s Interim Chief Executive Officer and Interim Chief Financial Officer on June 20, 2023.
Effective June 19, 2023, Leet Technology Inc. Company’s Board of Directors (the “Board”) appointed Mr. Jayaisvaran A/L Muruhan to serve as Interim Chief Financial Officer, while the Board evaluates an expanded pool of candidates for the permanent position.
On June 13, 2023, MedMen Enterprises Inc. (the “Company”) was notified of the resignation by Ana Bowman from her position as Chief Financial Officer of the Company, which resignation will be effective June 29, 2023.
Kiva Allgood ceased to be Chief Executive Officer of the Company and its subsidiaries (together, the “Company Group”) on May 11, 2023
On June 16, 2023, the Board appointed Michael Hand as interim Chief Financial Officer, effective as of July 1, 2023
On June 16, 2023, Amy "Levy" Trooskin, Chief Financial Officer of Vince Holding Corp. (the “Company”), notified the Company’s Board of Directors (the “Board”) of her decision to resign from her position to pursue another opportunity, effective June 30, 2023.
each Executive Officer will serve as a Co-Chief Executive Officer, with Mr. Godfrey primarily responsible for manufacturing operations and administrative functions and Mr. Graham primarily responsible for sales, marketing, growth initiatives, product offering and mix.
each Executive Officer will serve as a Co-Chief Executive Officer, with Mr. Godfrey primarily responsible for manufacturing operations and administrative functions and Mr. Graham primarily responsible for sales, marketing, growth initiatives, product offering and mix.
Effective June 12, 2023, the board of directors (the “Board”) of Newcourt Acquisition Corp (the “Company”), appointed Jurgen van de Vyver as Chief Financial Officer (the “CFO”) of the company.
the employment of Valerie Lightfoot as the Company’s Chief Financial Officer did not commence on June 12, 2023, as previously announced.
The Board appointed Dennis Curran, Acreage’scurrent Chief Operating Officer, to assume the roles of Chief Executive Officer and director on July 1, 2023.
Peter Caldini, who as previously announced will step down from the role of Chief Executive Officer on June 30, 2023, resigned from the Board effective as of the date of his resignation as CEO.
On June 14, 2023, Steven Ortega notified Applied Therapeutics, Inc. (the “Company”) that he will resign from his position as the Company’s Chief Accounting Officer and Interim Principal Financial Officer effective as of June 30, 2023, to pursue another professional opportunity.
On June 16, 2023, the Company appointed Catherine Thorpe as the interim Principal Financial Officer and Chief Accounting Officer, effective immediately, in light of Mr. Ortega’s anticipated departure and Mr. Ortega ceased to serve in such roles.
the Company had terminated the employment of Michael Darrow as President and Chief Executive Officer of the Company effective June 15, 2023.
As disclosed in the Original Form 8-K, the Company’s Board of Directors (the “Board”) appointed Kurt Wehner, the Company’s Chief Accounting Officer, as Chief Financial Officer and Treasurer effective June 1, 2023.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.